Objective To assess the effi cacy and safety of abatacept in biological-naive patients with rheumatoid arthritis and an inadequate response to methotrexate treated in the long-term extension (LTE) of the ATTEST trial. Methods Patients randomly assigned to abatacept, placebo or infl iximab completing the 1-year double-blind period were eligible to receive abatacept ~10 mg/kg in the open-label LTE. Effi cacy to year 2 is presented for patients randomly assigned to abatacept or infl iximab who switched to open-label abatacept. Safety data are presented for all patients entering LTE regardless of double-blind treatment.
Randomised clinical trials have assessed the efficacy and safety of switching to abatacept (T-cell costimulation modulator), rituximab (B-cell depleting therapy) or tocilizumab (interleukin-6 inhibitor) after failure of anti-tumour necrosis factor (TNF) agents. [1] [2] [3] [4] [5] However, there is a paucity of information on the effi cacy and safety of switching from one mechanism of action to another in patients who have not failed previous anti-TNF therapy due to lack of effi cacy.
The Abatacept or infl iximab versus placebo, a Trial for Tolerability, Effi cacy and Safety in Treating rheumatoid arthritis (ATTEST) trial provided a unique opportunity to assess clinical effi cacy and safety outcomes in biological-naive patients who switched from an anti-TNF to abatacept, regardless of earlier treatment response − that is including both patients in high, moderate or low disease states, or with American College of Rheumatology (ACR) 20, 50 or 70 responses, at the end of 12 months of infl iximab treatment. Such observations could help inform clinical decision-making following treatment withdrawal for either safety or effi cacy-related reasons. In the 1-year double-blind period of ATTEST, although a greater proportion of patients achieved ACR20 at month 1 with infl iximab versus abatacept, by month 3 responses were similar. Both biological agents demonstrated comparable effi cacy compared with placebo at 6 months; further improvements were observed with abatacept over 1 year. 6 There were numerically fewer serious adverse events (SAE) and serious infections with abatacept versus infl iximab over 1 year.
Here, we report the effi cacy and safety from the 1-year open-label long-term extension (LTE) of ATTEST, in which all patients received open-label abatacept, regardless of double-blind treatment or treatment response.
METHODS

Patients and study design
Patients had an inadequate response to methotrexate with active disease at randomisation, as previously described. 6 Patients were randomly assigned (3:3:2), using a double-dummy regimen, 6 to receive intravenous abatacept (~10 mg/kg based on weight range), infl iximab (fi xed-dose 3 mg/kg) or placebo, plus background methotrexate. Placebotreated patients were switched to abatacept at month 6. At month 12, patients from each treatment group could enter the open-label LTE, during which they received abatacept every 28 days. For patients switching from infl iximab, there was no washout period before the fi rst abatacept infusion. Patients were monitored monthly, at each study visit. During the open-label LTE, physicians could add a non-biological disease-modifying antirheumatic drug and adjust corticosteroid and methotrexate doses. The active-controlled ATTEST trial, requested by the authorities, was initially powered to detect reductions in disease activity with abatacept versus placebo over 6 months. Although not powered for, comparisons in safety and effi cacy 
RESULTS
Patient disposition, baseline demographics and clinical characteristics
Of the 431 patients originally randomly assigned to abatacept (n=156), infl iximab (n=165) or placebo (n=110), 344 (79.8%) patients remained on abatacept at year 2. Detailed patient disposition data are provided in supplementary fi gure 1 (available online only). Patient demographics and baseline clinical characteristics for patients who entered the LTE were consistent with those for the original randomly assigned population, 6 and were comparable between original groups (supplementary table A, available online only).
Concomitant medications
During the 1-year open-label LTE, 98.5% of all patients (both original abatacept and infl iximab arms) received concomitant methotrexate. Other than methotrexate, concomitant non-biological disease-modifying antirheumatic drugs administered during the LTE included azathioprine (for original abatacept and infl iximab arms, respectively; 0.8% vs 3.7%), hydroxychloroquine/chloroquine (1.5% vs 2.2%), lefl unomide (2.3% vs 3.7%) and sulfasalazine (4.5% vs 4.4%).
Clinical effi cacy
The proportions of patients achieving DAS28-defi ned LDAS and remission, and those achieving SDAI-defi ned low disease activity and remission are shown in fi gure 1A,B. Rates of LDAS and remission, according to both DAS28 and SDAI, increased numerically from year 1 to year 2 in the original abatacept group; for patients originally randomly assigned to infl iximab, rates increased following the switch to abatacept. ACR 50 and 70 responses, EULAR responses, reductions from baseline in DAS28 (ESR) and HAQ-DI scores are shown in the supplementary material available online only.
between abatacept and infl iximab were prespecifi ed. The primary objective of the open-label LTE, however, was to evaluate safety in patients who remained on treatment.
Effi cacy assessments
Clinical effi cacy was a secondary objective of this study, and results are presented at 6-month intervals during the open-label LTE for patients originally randomly assigned to either abatacept or infl iximab, who received at least one abatacept infusion in the LTE; data for patients randomly assigned to placebo are not shown. Disease activity was assessed by the disease activity score in 28 joints (DAS28; erythrocyte sedimentation rate (ESR), low disease activity state (LDAS) ≤3.2; remission <2.6), 7 and by the simplifi ed disease activity index (SDAI; low disease activity ≤11.0; remission ≤3.3). ACR 8 and EULAR responses 9 and health assessment questionnaire-disability index (HAQ-DI) 10 scores were recorded, and are provided in the supplementary information available online only. Results are shown for patients with data available at the visit of interest (as-observed analysis).
Patient-level, post-hoc analyses of shifts in ACR responses and DAS28 status from year 1 to year 2 were performed in patients who originally received infl iximab and then switched to abatacept. Mutually exclusive categories were used to defi ne ACR responses and DAS28 status, detailed in table 1.
Safety assessments
Adverse events were monitored monthly at each study visit. The safety of abatacept during the cumulative period (1-year doubleblind plus 1-year LTE) is presented as incidence rates (IR) for patients who received at least one infusion of abatacept, regardless of initial randomisation. In addition, events that occurred during open-label abatacept treatment in patients originally randomly assigned to infl iximab are shown alongside events that occurred in the double-blind period with abatacept or infl iximab for comparison. 
DISCUSSION
The ATTEST trial provided an opportunity to assess the effi cacy of abatacept over 2 years while concurrently evaluating patients who were switched to abatacept after initial treatment with infl iximab. In the original abatacept group, improvements in disease activity achieved by the end of the double-blind period were maintained with continued abatacept treatment through the LTE. For patients switched from infl iximab to abatacept at year 1, clinical effi cacy benefi ts were maintained or increased following the switch. Observed effi cacy benefi ts are supported by good retention rates, consistent with previous abatacept experience in this population. 11 12 The majority of individual patients who switched to abatacept improved or maintained their treatment response or disease activity level at year 2, regardless of the initial response to infl iximab. Many patients who had not achieved a response, or were still in high/moderate disease activity after 1 year of infl iximab, achieved a response or improved their disease activity state with abatacept. In addition, the majority of patients achieving ACR 70 responses or DAS28 remission with infl iximab maintained this response or state when switched. These data reassure the clinician that a patient treated with infl iximab, who has experienced a good clinical response, may expect to have a continued good response with consistent safety if they
Patient-level clinical effi cacy analyses
After 1 year of infl iximab treatment, 30.7% of patients were ACR 20 non-responders, and 25.2%, 18.9% and 25.2% achieved ACR 20, 50 and 70 responses, respectively, with 31.2%, 44.8%, 9.6% and 14.4% of patients in high disease activity state, moderate disease activity state (MDAS), LDAS and remission, respectively. Table 1 shows the shifts in ACR responses and DAS28 states for these patients from years 1 to 2.
Safety
Abatacept was generally well tolerated over the cumulative 2-year study period (table 2). Osteoarthritis (fi ve patients) was the only SAE reported in 1% or more of patients, other than worsening of rheumatoid arthritis. Two deaths were reported in the open-label period (respiratory failure and accidental).
The most common infections (≥10% of patients) were nasopharyngitis, urinary tract infection, upper respiratory tract infection, infl uenza and pharyngitis; and for serious infections were pneumonia and urinary tract infection (three patients each). There was a single report of latent tuberculosis during the LTE in a patient originally randomly assigned to infl iximab, considered severe. The patient had a negative chest x-ray and purifi ed protein derivative (PPD) test at study entry, and a positive PPD test and chronic bronchitis and basal fi brosis on x-ray at month 6 of the LTE; the patient did not discontinue and the event resolved after approximately 1 year.
Two malignancies were reported in the LTE, including basal cell carcinoma in a patient originally randomly assigned to abatacept, which was classifi ed as serious and possibly related to treatment.
All autoimmune events were mild or moderate in intensity; psoriasis was the most frequent event and was reported in three patients.
Acute infusional adverse events occurred in 11 patients originally randomly assigned to infl iximab after they switched to abatacept. The most common events (≥1% of patients) were headache, dizziness and nausea. are switched to abatacept; an important clinical consideration if patients are switched because of safety concerns. Abatacept was generally safe and well tolerated during this study. Transitioning patients directly from infl iximab to abatacept without a washout period did not result in higher overall frequencies of SAE or infections after switching medication, relative to previous double-blind infl iximab treatment over 1 year; in particular, incidence rates of serious and opportunistic infections were lower after patients switched to abatacept. These data support previously published fi ndings that demonstrated that switching directly from an anti-TNF to abatacept without a washout period was generally safe and well tolerated. 4 The fi ndings presented here should be considered within certain limitations. Effi cacy data are based on as-observed analyses, which are vulnerable to dropouts; however, discontinuation rates were relatively low and, therefore, the fi ndings probably provide an accurate representation of the randomly assigned population. It should be noted that the patient-level results reported here are post-hoc analyses, and caution should be used with such data. During the 1-year double-blind period, the infl iximab dose could not be increased beyond 3 mg/kg, the recommended dosing regimen at the time of trial design. In the current clinical setting, many physicians use approved higher doses, although there has been extensive debate over the effi cacy benefi ts of such dose escalation [13] [14] [15] and reports of an increased incidence of infections with higher doses. 16 However, the objective of the current study was to assess safety and effi cacy in patients who switch to abatacept, regardless of treatment response, and, thus, included patients responding to treatment with infl iximab. Therefore, the fact that dose escalation of infl iximab was not permitted in the double-blind period should not detract from these fi ndings.
The defi nition of an 'inadequate response' to therapy is changing, with clinical remission a clear therapeutic goal and LDAS an acceptable alternative in patients with long-standing, established disease. 17 As such, patients and clinicians now have ever higher expectations of treatment. Physicians may consider switching patients who have achieved only moderate clinical improvements, such as an ACR 20 response or MDAS. The fi ndings presented here suggest that abatacept is a viable treatment option for such patients.
